Insider Transactions in Q2 2017 at Cvs Health Corp (CVS)
Insider Transaction List (Q2 2017)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 26
2017
|
Helena Foulkes EVP & President-CVS Pharmacy |
SELL
Open market or private sale
|
Direct |
20,333
-31.12%
|
$1,626,640
$80.0 P/Share
|
|
Jun 26
2017
|
Helena Foulkes EVP & President-CVS Pharmacy |
BUY
Exercise of conversion of derivative security
|
Direct |
20,333
+13.94%
|
$691,322
$34.96 P/Share
|
|
Jun 19
2017
|
Helena Foulkes EVP & President-CVS Pharmacy |
SELL
Open market or private sale
|
Direct |
20,332
-31.12%
|
$1,545,232
$76.98 P/Share
|
|
Jun 19
2017
|
Helena Foulkes EVP & President-CVS Pharmacy |
BUY
Exercise of conversion of derivative security
|
Direct |
20,332
+13.94%
|
$691,288
$34.96 P/Share
|
|
Jun 12
2017
|
David M Denton EVP and CFO |
SELL
Open market or private sale
|
Direct |
230,510
-58.35%
|
$18,440,800
$80.0 P/Share
|
|
Jun 12
2017
|
David M Denton EVP and CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
230,510
+18.57%
|
$9,220,400
$40.1 P/Share
|
|
May 10
2017
|
David W Dorman Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,521
+4.42%
|
$281,680
$80.94 P/Share
|
|
May 10
2017
|
Nancy Ann Deparle Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,297
+14.11%
|
$103,760
$80.94 P/Share
|
|
May 10
2017
|
Richard M Bracken Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,389
+17.31%
|
$111,120
$80.94 P/Share
|
|
May 10
2017
|
Jean Pierre Millon Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,297
+50.0%
|
$103,760
$80.94 P/Share
|
|
May 10
2017
|
Tony L White Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,297
+5.34%
|
$103,760
$80.94 P/Share
|
|
Apr 03
2017
|
Robert O. Kraft EVP and President - Omnicare |
BUY
Grant, award, or other acquisition
|
Direct |
5,124
+5.26%
|
$399,672
$78.05 P/Share
|
|
Apr 03
2017
|
Jonathan C Roberts EVP & Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,624
+26.58%
|
$1,998,672
$78.05 P/Share
|
|
Apr 03
2017
|
Helena Foulkes EVP & President-CVS Pharmacy |
BUY
Grant, award, or other acquisition
|
Direct |
19,218
+27.29%
|
$1,499,004
$78.05 P/Share
|
|
Apr 03
2017
|
Larry J Merlo Director |
BUY
Grant, award, or other acquisition
|
Direct |
43,241
+19.02%
|
$3,372,798
$78.05 P/Share
|
|
Apr 03
2017
|
Thomas M Moriarty EVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
16,015
+26.83%
|
$1,249,170
$78.05 P/Share
|
|
Apr 03
2017
|
David M Denton EVP and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
12,812
+7.73%
|
$999,336
$78.05 P/Share
|
|
Apr 03
2017
|
Troyen A Brennan EVP and Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,609
+22.3%
|
$749,502
$78.05 P/Share
|
|
Apr 03
2017
|
Stephen J Gold EVP & CIO |
BUY
Grant, award, or other acquisition
|
Direct |
8,648
+15.59%
|
$674,544
$78.05 P/Share
|
|
Apr 03
2017
|
Lisa Bisaccia Former EVP & Chief HR Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,046
+23.39%
|
$549,588
$78.05 P/Share
|
|
Apr 03
2017
|
Andrew Sussman EVP, Clinical Services |
BUY
Grant, award, or other acquisition
|
Direct |
4,804
+22.62%
|
$374,712
$78.05 P/Share
|
|
Apr 03
2017
|
Eva C Boratto EVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
4,484
+22.24%
|
$349,752
$78.05 P/Share
|
|
Apr 03
2017
|
J. David Joyner President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
4,484
+21.87%
|
$349,752
$78.05 P/Share
|
|
Apr 02
2017
|
Jonathan C Roberts EVP & Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,655
-12.1%
|
$363,090
$78.5 P/Share
|
|
Apr 02
2017
|
Helena Foulkes EVP & President-CVS Pharmacy |
SELL
Payment of exercise price or tax liability
|
Direct |
2,394
-5.05%
|
$186,732
$78.5 P/Share
|
|
Apr 02
2017
|
Larry J Merlo Director |
SELL
Payment of exercise price or tax liability
|
Direct |
19,944
-5.98%
|
$1,555,632
$78.5 P/Share
|
|
Apr 02
2017
|
David M Denton EVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,649
-3.88%
|
$518,622
$78.5 P/Share
|
|
Apr 02
2017
|
Troyen A Brennan EVP and Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,990
-4.92%
|
$311,220
$78.5 P/Share
|
|
Apr 02
2017
|
Lisa Bisaccia Former EVP & Chief HR Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,862
-3.97%
|
$145,236
$78.5 P/Share
|
|
Apr 02
2017
|
Andrew Sussman EVP, Clinical Services |
SELL
Payment of exercise price or tax liability
|
Direct |
1,596
-12.04%
|
$124,488
$78.5 P/Share
|
|
Apr 02
2017
|
J. David Joyner President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,862
-2.5%
|
$145,236
$78.5 P/Share
|
|
Apr 01
2017
|
Larry J Merlo Director |
SELL
Payment of exercise price or tax liability
|
Direct |
12,906
-3.73%
|
$1,006,668
$78.5 P/Share
|
|
Apr 01
2017
|
Thomas M Moriarty EVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
2,617
-8.3%
|
$204,126
$78.5 P/Share
|
|
Apr 01
2017
|
David M Denton EVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,420
-1.39%
|
$188,760
$78.5 P/Share
|
|
Apr 01
2017
|
Troyen A Brennan EVP and Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,097
-2.52%
|
$163,566
$78.5 P/Share
|
|
Apr 01
2017
|
Stephen J Gold EVP & CIO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,396
-4.56%
|
$108,888
$78.5 P/Share
|
|
Apr 01
2017
|
Lisa Bisaccia Former EVP & Chief HR Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,291
-2.68%
|
$100,698
$78.5 P/Share
|
|
Apr 01
2017
|
Andrew Sussman EVP, Clinical Services |
SELL
Payment of exercise price or tax liability
|
Direct |
1,129
-7.85%
|
$88,062
$78.5 P/Share
|
|
Apr 01
2017
|
Eva C Boratto EVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,705
-6.56%
|
$210,990
$78.5 P/Share
|
|
Apr 01
2017
|
J. David Joyner President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
847
-1.12%
|
$66,066
$78.5 P/Share
|